Treatment of XXXX with @entity4088 : a double-blind study.

@entity1 @entity662 @entity935 @entity191 @entity4088 @entity1833 @entity911 @entity1431
@entity4088 is a potent @entity935 agonist and is known to have anti-Parkinson properties. We administered @entity4088 to @entity1 with suboptimal control of @entity191 who had a short-duration response to carbidopa-levodopa in a 6-month, double-blind study. @entity4088 added to the carbidopa-levodopa regimen resulted in both subjective and objective improvement in comparison with placebo. In @entity1 who tolerated @entity4088 , the median time spent in the "off" ( @entity191 ) state was reduced from 5.0 to 2.2 hours daily (compared with a 0.3-hour reduction in the placebo group). These @entity1 were able to decrease the median frequency of carbidopa-levodopa dosage from 7.5 to 5.0 doses daily (no change in the placebo group). Prolongation of the "on" response (optimal response to treatment) to single doses of drugs was corroborated by monitoring of the @entity1 ' Parkinson response cycle. The peak response was also improved in most @entity1 . Of 25 @entity1 randomized to the @entity4088 group, 7 were unable to tolerate this drug; @entity911 or @entity1833 occurred in 4 of these @entity1 , and @entity662 , @entity1431 , and nonspecific dizziness, respectively, developed in the other 3. All adverse events were reversible with reduction of the dose or discontinuation of the @entity4088 regimen. In conclusion, @entity1 with @entity191 who experience clinical fluctuations with carbidopa-levodopa may be helped by the addition of @entity4088 to the therapeutic regimen.
